



(51) International Patent Classification:

A61K 38/26 (2006.01) A61P 3/04 (2006.01)
A61K 31/13 (2006.01) A61P 3/06 (2006.01)
A61K 47/54 (2017.01) A61P 3/10 (2006.01)
A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2023/071477

(22) International Filing Date:

02 August 2023 (02.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/395,783 05 August 2022 (05.08.2022) US

(71) Applicant: INDIANA UNIVERSITY RESEARCH AND
TECHNOLOGY CORPORATION [US/US]; 107 S. In-
diana Avenue, Bloomington, Indiana 47405 (US).

(72) Inventors: DIMARCHI, Richard D.; 10890 Wilmington
Drive, Carmel, Indiana 46033 (US). MROZ, Piotr An-
drzej; 1207 S. Paper Birch Court, Bloomington, Indiana

47403 (US). THALLURI, Kishore; 4303 W. Cherry Or-
chard Court, Bloomington, Indiana 47403 (US).

(74) Agent: BREEN, John P. et al.; BARNES & THORN-
BURG LLP, 11 South Meridian Street, Indianapolis, Indi-
ana 46204 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS

Seq #16 = MBX-1245




Fig. 1

(57) Abstract: Glucagon-like peptide-1 (GLP-1) plays an important role in regulating blood glucose levels in humans. Its actions include stimulation of insulin synthesis and secretion, inhibition of glucagon secretion, and inhibition of food intake. Provided herein are GLP-1 receptor antagonists peptides and pharmaceutical compositions for the treatment of hypoglycemia. Further provided herein are methods of treating atypical hypoglycemia in patients that have become hyperinsulinemic, including those who become hyperinsulinemic after bariatric surgery.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

18 April 2024 (18.04.2024)